Melatonin lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with CHD
The hormone Melatonin is best known for its impact on sleep and circadian rhythms, however it provides many additional health benefits.
The published paper I want to share with you today refers to its potential benefits for individuals who deal with Type ll Diabetes with CHD: but also it cautions about a common gene variant (30 % of the population) in which typical Melatonin dosages may create problems.
Here are a couple of highlights from the paper:
CONCLUSIONS: Overall, melatonin intake for 12 weeks to diabetic patients with CHD had beneficial effects on plasma GSH, NO, MDA, PCO, serum hs-CRP levels, glycemic control, HDL-cholesterol, total-/HDL-cholesterol ratio, blood pressures and parameters of mental health.
And 6 Key Takeaways: